Chemotherapy + Immunotherapy for Hodgkin's Lymphoma
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, you cannot use other anti-cancer agents or experimental treatments while participating in this trial.
What data supports the effectiveness of the drug combination used in the Chemotherapy + Immunotherapy for Hodgkin's Lymphoma trial?
Research shows that a similar drug combination, including doxorubicin, vinblastine, and dacarbazine, has been effective in treating advanced Hodgkin's lymphoma, with some patients achieving long-term remission. Additionally, pembrolizumab, part of the trial's drug combination, has shown promise in treating relapsed Hodgkin's lymphoma when combined with other chemotherapy drugs.12345
Is the combination of chemotherapy and immunotherapy safe for treating Hodgkin's Lymphoma?
The safety of chemotherapy drugs like doxorubicin, vinblastine, and dacarbazine, often used in combination treatments for Hodgkin's Lymphoma, has been evaluated in several studies. These studies generally show that while these drugs can be effective, they may also cause side effects, which are common in cancer treatments. It's important to discuss potential risks and benefits with your healthcare provider.14678
How is the chemotherapy and immunotherapy drug combination for Hodgkin's Lymphoma unique?
This treatment combines chemotherapy drugs (Dacarbazine, Doxorubicin, Vinblastine) with an immunotherapy drug (Pembrolizumab), which is unique because it leverages the body's immune system to help fight cancer cells, potentially offering a new approach compared to traditional chemotherapy regimens alone.19101112
What is the purpose of this trial?
This phase II trial studies the side effects of doxorubicin hydrochloride, pembrolizumab, vinblastine, and dacarbazine in treating patients with classical Hodgkin lymphoma. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with pembrolizumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving doxorubicin hydrochloride, pembrolizumab, vinblastine, and dacarbazine may work better in treating classical Hodgkin lymphoma.
Research Team
Ryan Lynch, MD
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Eligibility Criteria
This trial is for patients with untreated classical Hodgkin lymphoma. Eligible participants include those who are not pregnant, agree to use birth control, have a good performance status (able to carry out daily activities), and adequate organ function. It's not open to individuals with severe heart conditions, active infections, other cancers (except certain skin or in situ cancers), HIV/hepatitis B/C, or those on oxygen therapy.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part A
Patients receive doxorubicin hydrochloride, vinblastine, and dacarbazine IV on days 1 and 15, and pembrolizumab IV on days 1 and 22 of cycle 1 and on day 15 of cycle 2. Treatment repeats every 28 days for up to 2 cycles.
Treatment Part B
Patients receive doxorubicin hydrochloride, vinblastine, dacarbazine, and pembrolizumab IV as in Part A, but undergo a total of 6 treatment cycles.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion, with follow-up at 30 days and then up to 5 years.
Treatment Details
Interventions
- Dacarbazine
- Doxorubicin Hydrochloride
- Pembrolizumab
- Vinblastine
Dacarbazine is already approved in United States, European Union, Canada for the following indications:
- Hodgkin lymphoma
- Melanoma
- Soft tissue sarcoma
- Hodgkin lymphoma
- Melanoma
- Soft tissue sarcoma
- Hodgkin lymphoma
- Melanoma
- Soft tissue sarcoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Washington
Lead Sponsor